Odinak M M, Skvortsova V I, Vozniuk I A, Rumiantseva S A, Stakhovskaia L V, Klocheva E G, Novikova L B, Ianishevskiĭ S N, Golokhvastov S Iu, Tsygan N V
Zh Nevrol Psikhiatr Im S S Korsakova. 2010;110(12):29-36.
We present the results of a multicenter study on efficacy of cytoflavin in the treatment of patients with acute ischemic stroke. Seventy patients (41 of the main group and 29 of the control group) were enrolled in the study. All patients received basic therapy aimed at improving systemic hemodynamics, rheological blood properties and at the prevention of stroke complications. Patients of the main group were treated with cytoflavin as follows: days 1-10 - 20 ml (in 400 ml of the 0,9% NaCl solution) twice a day intravenously in drops; days 11-35 - 850 mg twice a day. We assessed the dynamics of restoration of lost functions (NIHSS, the Rankin scale, the Barthel index) and volumes of ischemic lesion (MRI T1-, T2-, diffusion-weighted images). Results of the study on patients of the control group were supplemented with literature data about 306 patients studied using clinical scales and 40 patients studied with MRI. We revealed a trend towards an effect of cytoflavin on the preservation of brain matter in the acute phase of stroke. Cytoflavin reduced the neurological deficit and improved activities of daily living in patients that may be explained by the less brain damage.
我们展示了一项关于细胞色素C在治疗急性缺血性中风患者中疗效的多中心研究结果。70名患者（41名在主要治疗组，29名在对照组）参与了该研究。所有患者均接受旨在改善全身血流动力学、血液流变学特性以及预防中风并发症的基础治疗。主要治疗组的患者接受细胞色素C治疗如下：第1 - 10天，20毫升（溶于400毫升0.9%氯化钠溶液中），每日两次静脉滴注；第11 - 35天，850毫克，每日两次。我们评估了丧失功能的恢复动态（美国国立卫生研究院卒中量表、Rankin量表、巴氏指数）以及缺血性病变的体积（MRI T1、T2、扩散加权图像）。对照组患者的研究结果补充了关于306名使用临床量表研究的患者以及40名使用MRI研究的患者的文献数据。我们发现细胞色素C在中风急性期对脑实质具有保护作用的趋势。细胞色素C减少了患者的神经功能缺损并改善了日常生活活动能力，这可能是由于脑损伤较轻所致。
